The study identified new potentially oncogenic gene fusions, some of which activate oncogenes like PTK2, PDGFRA and GSK3B, or disrupt tumour suppressors like STK11, STK4 and ATM. Phosphoproteomic analyses linked these fusions to specific activated pathways, providing insights into potential therapeutic targets. The gene discussed is STK11; the disease is neoplasm.